DK1074268T3 - IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme - Google Patents

IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme

Info

Publication number
DK1074268T3
DK1074268T3 DK99907951T DK99907951T DK1074268T3 DK 1074268 T3 DK1074268 T3 DK 1074268T3 DK 99907951 T DK99907951 T DK 99907951T DK 99907951 T DK99907951 T DK 99907951T DK 1074268 T3 DK1074268 T3 DK 1074268T3
Authority
DK
Denmark
Prior art keywords
inflammatory bowel
preventative
therapeutic agents
receptor antagonist
antagonist antibody
Prior art date
Application number
DK99907951T
Other languages
Danish (da)
English (en)
Inventor
Tadamitsu Kishimoto
Mitsunari Yamamoto
Hiroaki Ito
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13339502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1074268(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1074268T3 publication Critical patent/DK1074268T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK99907951T 1998-03-17 1999-03-16 IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme DK1074268T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6725098 1998-03-17
PCT/JP1999/001298 WO1999047170A1 (fr) 1998-03-17 1999-03-16 Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant, comme ingredient actif, des antagonistes de il-6

Publications (1)

Publication Number Publication Date
DK1074268T3 true DK1074268T3 (da) 2008-04-28

Family

ID=13339502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99907951T DK1074268T3 (da) 1998-03-17 1999-03-16 IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme

Country Status (19)

Country Link
US (2) US6723319B1 (ko)
EP (1) EP1074268B1 (ko)
JP (1) JP4124573B2 (ko)
KR (1) KR100407811B1 (ko)
CN (2) CN100374159C (ko)
AT (1) ATE383875T1 (ko)
AU (1) AU754006B2 (ko)
CA (1) CA2324115C (ko)
CZ (1) CZ297083B6 (ko)
DE (1) DE69937994T2 (ko)
DK (1) DK1074268T3 (ko)
ES (1) ES2299241T3 (ko)
HK (2) HK1033911A1 (ko)
HU (1) HU225539B1 (ko)
NO (1) NO327718B1 (ko)
PL (1) PL201461B1 (ko)
PT (1) PT1074268E (ko)
RU (1) RU2195960C2 (ko)
WO (1) WO1999047170A1 (ko)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CN1306963C (zh) * 1994-10-21 2007-03-28 岸本忠三 用于治疗il-6产生所致疾病的药物组合物
CA2284271C (en) 1997-03-21 2012-05-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
JP4124573B2 (ja) * 1998-03-17 2008-07-23 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
AU775483B2 (en) * 1998-06-10 2004-08-05 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
DK1475101T3 (da) 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
AU2003261787B2 (en) * 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1673396A1 (en) * 2003-09-22 2006-06-28 BioVation GmbH & Co.KG. Use of antibodies for reducing the biological effectiveness of il-6
EP1690550B1 (en) 2003-10-17 2012-08-08 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for mesothelioma
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
EP3736295A1 (en) 2004-03-24 2020-11-11 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
JP5620626B2 (ja) * 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
US8945558B2 (en) * 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
US20090269335A1 (en) * 2005-11-25 2009-10-29 Keio University Therapeutic agent for prostate cancer
ES2685915T3 (es) * 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
BRPI0715115A2 (pt) 2006-08-03 2013-06-04 Vaccinex Inc anticorpo monoclonal isolado, molÉcula de Ácido nucleico isolada, vetor de expressço, cÉlula hospedeira, mÉtodos para tratar uma doenÇa, e para produzir um anticorpo monoclonal isolado, uso do anticorpo monoclonal isolado, e, composiÇço farmacÊutica
CN101528778A (zh) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 用于治疗与il-6-介导的信号传导相关的疾病和病症的针对il-6r的氨基酸序列以及包括其的多肽
JP2010510796A (ja) * 2006-11-30 2010-04-08 アストラゼネカ アクチボラグ インターロイキン−6とインターロイキン−6受容体との複合体に特異的な抗体
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤
TWI438208B (zh) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd 抑制慢性排斥反應之藥劑
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
MX343879B (es) * 2007-05-21 2016-11-25 Alderbio Holdings Llc Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
TWI561530B (en) * 2007-05-21 2016-12-11 Alderbio Holdings Llc Antibodies to il-6 and use thereof
WO2009041621A1 (ja) * 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
KR101840994B1 (ko) * 2007-12-05 2018-03-21 추가이 세이야쿠 가부시키가이샤 항nr10 항체 및 그의 이용
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP3056513A1 (en) 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
DK2297202T3 (en) 2008-05-13 2016-03-21 Novimmune Sa ANTI-IL-6 / IL-6R ANTIBODIES AND PROCEDURES FOR USE THEREOF
TW201503898A (zh) * 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
MX337590B (es) * 2009-01-29 2016-03-11 Medimmune Llc Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
US9340615B2 (en) 2009-05-15 2016-05-17 Chugai Seiyaku Kabushiki Kaisha Anti-AXL antibody
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2493922B1 (en) 2009-10-26 2017-02-15 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
KR20210021109A (ko) 2010-11-08 2021-02-24 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
EP2643018B1 (en) 2010-11-23 2020-10-14 AlderBio Holdings LLC Anti-il-6 antibodies for the treatment of oral mucositis
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ang2 항체를 함유하는 안정화된 제형
CN104349787B (zh) 2012-05-21 2019-02-15 韩国生命工学研究院 含有荔枝草提取物或其馏分作为活性成分的预防或治疗stat-3介导疾病的药物组合物
US10822420B2 (en) * 2012-09-13 2020-11-03 Chugai Seiyaku Kabushiki Kaisha Gene knock-in non-human animal
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
JP7128460B2 (ja) 2015-06-04 2022-08-31 国立研究開発法人国立精神・神経医療研究センター Il-6阻害剤を有効成分とする精神疾患治療剤
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MX2019008949A (es) 2017-01-27 2019-10-07 Stemrim Inc Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
SG10201912128SA (en) 2017-02-01 2020-02-27 Univ Yale Treatment of diuretic resistance
CN110603057A (zh) 2017-03-17 2019-12-20 俄亥俄州创新基金会 用于递送化学预防剂的纳米颗粒
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
EP3698808A4 (en) 2017-10-20 2021-07-14 Hyogo College Of Medicine MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION
BR112020013519A2 (pt) 2018-01-05 2020-12-01 Corvidia Therapeutics, Inc método para tratamento de uma inflamação.
SG11202009010RA (en) 2018-03-15 2020-10-29 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
WO2020160465A1 (en) 2019-01-31 2020-08-06 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20230293636A1 (en) * 2019-12-31 2023-09-21 Peptinov Pharmaceutical composition for the prevention or treatment of post-surgical pain
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) * 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US6428979B1 (en) * 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Bsf▲下2▼アンタゴニスト
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
PT97124A (pt) 1990-03-23 1991-12-31 Gist Brocades Nv Processo para a prparacao de composicoes inibidoras de interleucina - 6 (il-6)
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (en) 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
JPH07324097A (ja) * 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン6拮抗剤、及びペプチド類または医薬として許容されるその塩類
JPH10501815A (ja) 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的t細胞応答の阻害方法
NZ288997A (en) 1994-06-24 1999-01-28 Immunex Corp Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate
JPH0850829A (ja) 1994-08-05 1996-02-20 Tokai Rika Co Ltd レバースイッチ
US6010871A (en) 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
EP2107070A1 (en) 1994-10-07 2009-10-07 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as active ingredient
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il-6产生所致疾病的药物组合物
JPH08245414A (ja) 1995-01-27 1996-09-24 Private Biolog Corp Il−6関連疾患の治療用組成物および方法
ATE330629T1 (de) 1995-02-13 2006-07-15 Chugai Pharmaceutical Co Ltd Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
JPH08311098A (ja) * 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン6拮抗剤
US5571513A (en) 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
AU6038196A (en) 1995-06-07 1996-12-30 Private Biologicals Corporation Compositions and methods of treating il-6 associated disease s
WO1997024340A1 (en) 1995-12-27 1997-07-10 Takeda Chemical Industries, Ltd. Oxazole derivatives, their production and use
JPH09235276A (ja) * 1995-12-27 1997-09-09 Takeda Chem Ind Ltd オキサゾール誘導体、その製造法および用途
DK0907737T3 (da) * 1996-04-09 2005-06-27 Applied Research Systems IL-6-mutein
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
JP4124573B2 (ja) * 1998-03-17 2008-07-23 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
AU775483B2 (en) * 1998-06-10 2004-08-05 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
MXPA04009243A (es) * 2002-04-12 2005-06-08 Pfizer Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Also Published As

Publication number Publication date
ES2299241T3 (es) 2008-05-16
NO327718B1 (no) 2009-09-14
CN1297357A (zh) 2001-05-30
KR100407811B1 (ko) 2003-12-01
AU2748199A (en) 1999-10-11
WO1999047170A1 (fr) 1999-09-23
KR20010041933A (ko) 2001-05-25
DE69937994D1 (de) 2008-03-06
HUP0101694A1 (hu) 2002-12-28
NO20004581D0 (no) 2000-09-14
CA2324115C (en) 2008-12-23
HK1033911A1 (en) 2001-10-05
CZ20003297A3 (cs) 2001-02-14
PT1074268E (pt) 2008-02-28
HK1036018A1 (en) 2001-12-21
AU754006B2 (en) 2002-10-31
NO20004581L (no) 2000-11-10
EP1074268B1 (en) 2008-01-16
CA2324115A1 (en) 1999-09-23
US20040071706A1 (en) 2004-04-15
DE69937994T2 (de) 2008-12-24
US7824674B2 (en) 2010-11-02
US6723319B1 (en) 2004-04-20
JP4124573B2 (ja) 2008-07-23
ATE383875T1 (de) 2008-02-15
CZ297083B6 (cs) 2006-09-13
RU2195960C2 (ru) 2003-01-10
PL342938A1 (en) 2001-07-16
EP1074268A1 (en) 2001-02-07
PL201461B1 (pl) 2009-04-30
CN101239185A (zh) 2008-08-13
HU225539B1 (en) 2007-02-28
CN100374159C (zh) 2008-03-12
EP1074268A4 (en) 2002-11-20
HUP0101694A3 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
DK1074268T3 (da) IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
DK1108435T3 (da) Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
AU1095202A (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
NO933239D0 (no) Bioeroderbar innretning for administering av aktive ingredienser
DZ2686A1 (fr) Formulation pharmaceutique orale à libération pulsée.
FI941396A0 (fi) Koostumuksia biologisesti aktiivisen TGF-valvottua vapauttamista varten
DK0733628T3 (da) 5-substituerede 3-(1,2,3,6-tetrahydropyridin-4-yl)- og 3-(piperidin-4-yl)-1H-indoler: 5HT1F-agonister
NO975713D0 (no) Chelaterende polymere som kontrastmidler for medisinsk billeddannelse
FI970530A0 (fi) Koostumus aktiivisen aineen selektiiviseksi vapauttamiseksi
IT1295645B1 (it) Apparecchio per l'elettroemanazione di principi attivi.
DE69330631D1 (de) Trennmittel
DE69233090D1 (de) Trennmittel
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
TR28732A (tr) Hijyenik temizlik bilesimi ve bu bilesimi püskürtmeye mahsus cihaz.
NO982233L (no) Diagnostisk avbildningsmiddel
FR2747230B1 (fr) Bouton d'arret d'urgence cadenassable
FR2695297B1 (fr) Composition d'agent désinfectant.
KR970000260U (ko) 의자용 다리부의 결합장치
KR950022816U (ko) 발포제볼(Ball) 성형용 발포제 주입장치
KR970020844U (ko) 숫 송아지 거세 장치
IT9004855U1 (it) Nodo sferico per strutture metalliche reticolari spaziali.
FR2726970B1 (fr) Cage destinee plus particulierement au gardiennage d'animaux convalescents
ITBO980041A0 (it) Dispositivo per l'esercizio ginnico delle gambe.
NO890406D0 (no) Sitteanordning for pasienter.